Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CGEN: Collagen Aesthetics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: JoeinIowa who wrote (1)	12/2/2000 10:36:03 AM
From: JoeinIowa	Read Replies (1) \| Respond to of 8

Wednesday September 13, 8:05 am Eastern Time Press Release Compugen Completes Milestone in Multi-Year Pfizer Agreement TEL AVIV, Israel & JAMESBURG, N.J.--(BW HealthWire)--Sept. 13, 2000-- Collaboration Includes Compugen's LEADS Platform for Accelerated Genomic Discovery, DNA Chip Design and Z3 Software Package for 2D Gel and Proteomic Analysis Compugen Ltd., (NASDAQ:CGEN - news) announced today that it has completed the third milestone included in its agreement with Pfizer Global Research and Development (PGRD). The agreement provides Pfizer with LEADS, Compugen's advanced genomic discovery platform, DNA chip design, and Z3, Compugen's 2D gel analysis software package for advanced proteomic analysis. LEADS is an algorithm-driven bioinformatics platform for the analysis of genomic data, designed to help pharmaceutical, biotech, ag-bio and other life sciences companies accelerate the development of drugs and biological products. In late 1998, Compugen announced that the Parke-Davis division of Warner-Lambert Company, had become a LEADS Platform partner under a multi-year, multi-million dollar per year agreement. Compugen completed the first milestone in May 1999 and the second in November 1999. On June 19, 2000, Warner Lambert Company became a wholly-owned subsidiary of Pfizer Inc. (NYSE:PFE - news). The computational capabilities delivered to PGRD as part of this third milestone include the identification of predicted genes through clustering and assembly of genomic DNA and cDNA sequences that takes into consideration predicted splice variants and other features. LEADS' output provides scientists with putative genes and splice variants that can serve as a base for target identification, DNA chip design and other expression experiments. The two-fold challenge in the design process of DNA chip probes is in selecting specific, non redundant, error free probes that accurately reflect the genes of interest, and in ensuring differentiation between alternative splice variants of those genes. Compugen's chip design system adds new knowledge on gene expression and uses a semi-automatic design process in an effort to address these challenges. Based on LEADS technologies and Compugen's proprietary data, the system improves probe selection and provides sophisticated analysis of expression chip results both for Compugen-designed chips and for chips designed by alternative methodologies. Z3 is an image analysis system for two-dimensional gels. 2D gel analysis is the method of choice for separating complex mixtures of cellular proteins, however it is only partially exploited today because of the difficulties in analyzing the results. Z3 is designed to address these difficulties by automating the 2D gel analysis process. Z3's unique proprietary algorithms for gel comparison and for the computation of differential expression expedite, simplify and improve 2D gel analysis. Further, Z3 provides research oriented tools for the data mining and querying of information hidden in the gels, thus allowing users to run large scale experiments. Z3 will soon be available over the web as part of the suite of services offered by LabOnWeb.com, Compugen's Internet life science research engine for genomic, proteomic and transcriptomic analysis. About Compugen Compugen (www.cgen.com) is a pioneer in the field of computational genomics and is developing new approaches to computational proteomics. Compugen combines the disciplines of mathematics and computer science with molecular biology to improve its understanding of genomics and proteomics. Compugen develops products and services that enable life scientists to significantly enhance and accelerate their research efforts in the discovery of drugs, therapeutics, diagnostics and agricultural products. Compugen provides its corporate solutions to pharmaceutical, biotechnology and other life science organizations such as Pfizer, Human Genome Sciences, Inc. and the U.S. Patent and Trademark Office. In addition, Compugen provides these products and services to molecular biologists and other life scientists through its LabOnWeb.com Web site. Compugen is also commercializing the genes and proteins that it discovers through its Novel Genomics division. This press release contains ``forward-looking statements.'' These statements include expectations as to Compugen's release of new services on LabOnWeb, and other statements that include words like ``may,'' ``expects,'' ``believes,'' and ``intends,'' and that describe opinions about future events. These forward-looking statements are subject to risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially difference from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the impact of competitive products and technological changes; risks relating to the development of new products; the ability to implement technological improvements; the ability of Compugen to obtain and retain customers. These and other factors are identified and more fully explained under the heading ``Risk Factors'' in our Registration Statement on Form F-1 filed with the Securities and Exchange Commission. -------------------------------------------------------------------------------- Contact: Compugen Ltd. Tsipi Haitovsky, Director, Corporate Communications Tel: +972-3-7658120 Email: tsipi@cgen.com